CLR I C Novelty

1.
General
2.
State of the art
2.1.
General
2.2.
Applications with same filing or priority date
2.3.
Relevant date of documents
2.4.
Prior rights – Article 54(3) EPC
2.4.1
European prior rights
2.4.2
Applicability of Article 54(3) EPC in cases of potentially colliding European parent and divisional applications
2.4.3
Excluded national prior rights
2.4.4
PCT applications as state of the art
2.5.
Non-prejudicial disclosures under Article 55 EPC
2.6.
In-house knowledge not published before the priority date
2.7.
Prior art acknowledged in a patent application
2.8.
Common general knowledge
2.8.1
Definition of "common general knowledge"
2.8.2
Patent specifications as common general knowledge
2.8.3
Specialist journals as common general knowledge
2.8.4
Databases as common general knowledge
2.8.5
Proof of common general knowledge
3.
Availability to the public
3.1.
General
3.2.
Ways of making information available to the public
3.2.1
Publications and other printed documents
a)
General
b)
Company papers
c)
Advertising brochure
d)
Report available in the specialist field
e)
Books
f)
Instruction manual
g)
Patent and utility models
h)
Trade names
i)
Abstracts of documents
3.2.2
Lectures and oral disclosure
3.2.3
Internet disclosures
a)
General
b)
Public availability of a document stored on the World Wide Web
c)
Publication date
3.2.4
Public prior use
a)
General
b)
Public prior use occurred
c)
No public prior use
d)
Internal structure or composition of a product
3.2.5
Biological material
3.3.
The concept of "the public"
3.3.1
Sale to a single customer
3.3.2
Making available to a person not skilled in the art
3.3.3
A limited circle of people
3.3.4
Public library
3.4.
Obligation to maintain secrecy
3.4.1
General
3.4.2
Parts for serial production
3.4.3
Distribution of prospectuses, technical descriptions
3.4.4
Commercial inter-relationships and interests
3.4.5
Demonstrating products for presentation purposes
3.4.6
Presenting the product in writing
3.4.7
Making samples/products available for test purposes
3.4.8
Conferences
3.4.9
Public availability of documents submitted for standardisation
3.4.10
Joint venture and other commercial agreements
3.4.11
Paper submitted to obtain an academic degree
3.4.12
Medical field
3.4.13
Notary
3.5.
Evidence
3.5.1
Burden of proof
3.5.2
Standard of proof
a)
General
b)
Public prior use
c)
Internet – proof of the date of availability
4.
Determining the content of the relevant prior art
4.1.
General rules of interpretation
4.2.
Combinations within a prior art document
4.3.
Taking implicit features into account
4.4.
Taking intrinsic features into account
4.5.
Taking equivalents into account
4.6.
Taking drawings into account
4.7.
Taking examples into account
4.8.
Broad claims
4.9.
Deficiencies and mistakes in a disclosure
4.10.
Accidental disclosure
4.11.
Reproducibility of the content of the disclosure
5.
Ascertaining differences
5.1.
Comparing each individual item from the prior art
5.2.
Distinguishing features
5.2.1
Difference in wording
5.2.2
Differences in values
5.2.3
Difference in parameters
5.2.4
Difference in composition
5.2.5
Functional features
5.2.6
Generic disclosure
5.2.7
Product claim with process features
5.2.8
Non-technical distinguishing features
6.
Chemical inventions and selection inventions
6.1.
General
6.2.
Novelty of chemical compounds and groups of compounds
6.2.1
Anticipation of certain compounds
a)
Definition of a substance by its structural formula or other parameters
b)
Selection of starting substances from different lists
c)
Selection on the basis of a general formula
6.2.2
Novelty of groups of substances
6.2.3
Novelty of enantiomers
6.2.4
Achieving a higher degree of purity
6.3.
Selection of parameter ranges
6.3.1
Selection from a broad range
6.3.2
Overlapping ranges
6.3.3
Multiple selection
6.4.
Subject-matter group
7.
First and second medical use
7.1.
First medical use
7.1.1
Introduction
7.1.2
Scope of a purpose-related product claim
7.1.3
Protection of a preparation in the form of a "kit-of-parts"
7.1.4
Further technical information as compared with the state of the art
7.2.
Second (or further) medical use
7.2.1
Introduction
7.2.2
Transitional provisions
7.2.3
Purpose-limited product claims and Swiss-type claims – scope of protection
7.2.4
Novelty of the therapeutic application
a)
General
b)
New therapeutic application based on the group of subjects to be treated
c)
New technical effect
d)
Same illness
e)
New dosage regimen
f)
New therapy with a different mode of administration
g)
Interpretation of "substance or composition"
h)
Statement of purpose of surgical use for a known instrument
i)
Discovery of a previously unknown property of a compound underlying the known effect
j)
Whether there is a therapeutic method
8.
Second (or further) non-medical use
8.1.
Novelty criteria for use claims and process claims containing a purpose feature
8.1.1
General issues decided before the Enlarged Board of Appeal
8.1.2
Non-therapeutic treatment of animals
a)
Non-therapeutic application
8.1.3
Applicability of G 2/88 and G 6/88 to process claims
a)
General
b)
Different treatment of use and process claims
c)
Interpretation of process claims
d)
Use of a known process for a particular purpose
e)
Discovery of new properties/technical effects underlying the known use
f)
Use of a substance to achieve a technical effect only attained in special circumstances
8.1.4
Statement of purpose in non-medical use claims in view of Article 52(4) EPC 1973
8.1.5
Novelty criteria for product claims with purpose characteristics
 

Source: http://www.epo.org/law-practice/legal-texts/html/caselaw/2019/e/clr_i_c.htm

Date retrieved: 17 May 2021

143 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

Case Law Book

Case Law Book: I Patentability